Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Key Business Regulations to Consider While Arranging Your Independent venture - 2The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- 3New ‘Cloud-9’ object could reveal the secrets of dark matter
- 47 Fast Approaches to Let loose Space on Your Telephone in a flash
- 5Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
- Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- South Carolina's measles outbreak reaches 434 cases
- Burger King launches 'SpongeBob' menu ahead of film's release. A look at the Bikini Bottom-inspired meal, plus what taste testers are saying.
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Geomagnetic storm grounds launch of Mars space weather satellites
- Why screening for the deadliest cancer in the U.S. misses most cases
- Chinese mega embassy could bring security advantages, says No 10
- Treasure trove found in Egyptian tomb solves ancient mystery
- 'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
